Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant taxane + capecitabine versus taxane + anthracycline for stage II-III breast cancer
ACTRN12613000206729Phase 3Terminated
- Sponsor
- Peking University People's Hospital Breast Center
- Start
- Aug 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine, epirubicin, paclitaxel and docetaxel in breast cancer (2 arms), sponsored by Peking University People's Hospital Breast Center. Primary endpoint: Pathological complete response rate. Started Aug 2012; status: terminated.
02
Drugs
capecitabineepirubicinpaclitaxeldocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12613000206729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000206729.